Landscape Capital Management L.L.C. acquired a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 257,560 shares of the company's stock, valued at approximately $2,650,000.
Other hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Haleon during the 1st quarter worth approximately $58,870,000. Point72 Asset Management L.P. purchased a new stake in shares of Haleon in the fourth quarter valued at about $45,110,000. Wellington Management Group LLP lifted its stake in shares of Haleon by 22.0% in the first quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company's stock valued at $192,428,000 after purchasing an additional 3,372,155 shares during the period. Jane Street Group LLC raised its position in Haleon by 933.1% during the first quarter. Jane Street Group LLC now owns 2,155,716 shares of the company's stock worth $22,182,000 after acquiring an additional 1,947,050 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of Haleon by 27.7% during the fourth quarter. Northern Trust Corp now owns 5,412,542 shares of the company's stock worth $51,636,000 after buying an additional 1,172,931 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the stock. Morgan Stanley upgraded shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a research note on Friday, May 9th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Barclays restated an "overweight" rating on shares of Haleon in a report on Tuesday, May 6th. BNP Paribas Exane upgraded shares of Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 price objective for the company in a research note on Tuesday, May 27th. Finally, BNP Paribas raised shares of Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Haleon has a consensus rating of "Moderate Buy" and an average price target of $12.33.
Check Out Our Latest Research Report on Haleon
Haleon Stock Performance
HLN stock traded down $0.05 during midday trading on Tuesday, reaching $9.76. 8,451,276 shares of the company were exchanged, compared to its average volume of 12,693,559. The business has a 50-day moving average price of $9.83 and a two-hundred day moving average price of $10.22. The firm has a market capitalization of $43.74 billion, a price-to-earnings ratio of 24.99, a price-to-earnings-growth ratio of 2.89 and a beta of 0.23. Haleon PLC Sponsored ADR has a one year low of $8.86 and a one year high of $11.42. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63.
Haleon Increases Dividend
The company also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 18th. Stockholders of record on Friday, August 15th will be paid a $0.0555 dividend. This is an increase from Haleon's previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. The ex-dividend date of this dividend is Friday, August 15th. Haleon's payout ratio is currently 28.21%.
About Haleon
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Recommended Stories

Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.